Skip to content

RunaPharma

Active Private limited companyfounded 2010active for 16 yearsKantonbaan 9, 2520 RanstKBO/BCE: BE 0823.524.555

Annual accounts 2025

abbreviated format, filed on 09-12-2025, 53 days before the deadline
-€659
▲ €1,197
-€1,250
▲ €1,100
-€1,293
▲ €1,095
-€18,060
▼ €1,293
-
-

The abbreviated format does not require turnover, and these accounts state none. Without turnover there is no EBIT margin either.

Balance sheet

balance sheet total €189 on 30-06-2025
What the company ownsHow it is paid for

in euro

in euro

Key figures and ratios

per financial year, computed from the annual accounts
Line Trend202520242023202220212020201920182017no balance total20162015201420132012201116 months
-----------917-437-6,283-15,220-1,646
-----------979-521-6,281-15,975-1,873
----------00001,568
3575-9631,0357-37-1,006--320-652-1,421-32,47719,846-
-18,060-16,767-14,379-13,534-13,361-12,093-11,024-10,076--7,978-7,198-6,218-4,79730,58316,559
-------------3.9%81.7%
-------------8.715.19
-------------24.370.22
---------------13.1%
--------------46.1%-10.7%

The ratios are withheld because a balance sheet total of €189 is too small for a meaningful ratio.

A Belgian filing has no cash-flow statement. Cash flow is therefore an approximation, derived from the income statement. Investment is the acquisitions in the notes and, without them, the balance-sheet move.

Filed annual accounts

as filed with the National Bank, click a year to choose it
Line Trend202520242023202220212020201920182017no balance total20162015201420132012201116 months
Balance sheet: assets
20/58 189154791,04370371,043-32008342,56935,36021,630
21/28 -----------1834978101,124
22/27 -----------1834978101,124
23 -----------1834978101,124
29/58 189154791,04370371,043-32006522,07334,55020,506
40/41 --------------5,802
40 --------------4,293
41 --------------1,509
54/58 189154791,04370371,043-32006522,07334,55014,704
Balance sheet: equity and liabilities
10/49 189154791,04370371,043-32008342,56935,36021,630
10/15 -18,060-16,767-14,379-13,534-13,535-12,267-11,197-10,076-9,473-8,326-7,198-6,035-5,2011,39417,682
10/11 20,00020,00020,00020,00020,000020,00020,00020,00020,00020,00020,00020,00020,00020,000
100 -----020,00020,00020,00020,00020,00020,00020,00020,00020,000
11 -----20,000---------
1100/10 -----20,000---------
14 -38,060-36,767-34,379-33,534-33,535-32,267-31,197-30,076-29,473-28,326-27,198-26,035-25,201-18,606-2,318
17/49 18,24916,92214,45814,57613,54212,26711,23411,1199,4738,6457,1986,8707,77033,9673,948
17 -------------30,000-
170/4 -------------30,000-
42/48 18,24916,92214,45814,57613,36812,09311,06011,1199,4738,2987,1986,8706,8703,9673,948
43 ----------28----
430/8 ----------28----
44 --0118---58-------
440/4 --0118---58-------
45 -------------19-
450/3 -------------19-
47/48 18,24916,92214,45814,45813,36812,09311,06011,0609,4738,2987,1706,8706,8703,9483,948
492/3 ---0174174174--348--900--
Income statement
76A -------1,043-------
9900 -659-1,856-357139-790-593-797-107-654-534-324203-5,731-14,699-843
630 ----------183314314314444
640/8 590493450101448446270442440594593640552521802
9901 -1,250-2,349-80638-1,238-1,038-1,067-549-1,094-1,128-1,100-751-6,596-15,533-2,090
75/76B ---01--1--0-08910
75 ---01--1--0-08910
65/66B 443939373031545554-6384-2843236
65 443939373031545554-6384-2843236
9903 -1,293-2,388-8451-1,268-1,069-1,121-603-1,148-1,128-1,162-835-6,594-16,287-2,316
67/77 ------------021
9904 -1,293-2,388-8451-1,268-1,069-1,121-603-1,148-1,128-1,162-835-6,594-16,289-2,318
9905 -1,293-2,388-8451-1,268-1,069-1,121-603-1,148-1,128-1,162-835-6,594-16,289-2,318
Appropriation of the result
9906 -38,060-36,767-34,379-33,534-33,535-32,267-31,197-30,076-29,473-28,326-27,198-26,035-25,201-18,606-2,318
14P -36,767-34,379-33,534-33,535-----------
Document PDFPDFPDFPDFPDFPDFPDFPDFPDFPDFPDFPDFPDFPDFPDF

The full notes are in the filed accounts (PDF).

Source: Annual accounts 2025 (PDF), filed on 09-12-2025.

Download as CSV

Filings

each dot is a set of accounts, on the day it reached the National Bank
Financial year Type Filed Reference Document
30-06-2025 abbreviated format 09-12-2025 2025-00579347 PDF
30-06-2024 abbreviated format 17-01-2025 2025-00007080 PDF
30-06-2023 abbreviated format 11-12-2023 2023-00526804 PDF
30-06-2022 abbreviated format 19-12-2022 2022-20541788 PDF
30-06-2021 abbreviated format 21-12-2021 2021-80800448 PDF
30-06-2020 abbreviated format 29-01-2021 2021-02400484 PDF
30-06-2019 abbreviated format 23-01-2020 2020-01900106 PDF
30-06-2018 abbreviated format 20-12-2018 2018-74800540 PDF
30-06-2017 abbreviated format 19-12-2017 2017-72100211 PDF
30-06-2016 abbreviated format 06-12-2016 2016-69400365 PDF
30-06-2015 abbreviated format 07-12-2015 2015-68400060 PDF
30-06-2014 abbreviated format 08-12-2014 2014-68500279 PDF
30-06-2013 abbreviated format 11-12-2013 2013-68100469 PDF
30-06-2012 abbreviated format 04-12-2012 2012-65500086 PDF
30-06-2011 abbreviated format 07-12-2011 2011-63100006 PDF

Insights on RunaPharma

The operating result for 2025 is a loss of €1,250, smaller than the loss of €2,349 in 2024.

Equity is negative. Debt of €18,249 exceeds the balance-sheet total of €189.

Next steps